Full Text View
Tabular View
No Study Results Posted
Related Studies
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
This study has been completed.
Study NCT00920647   Information provided by Shire Human Genetic Therapies, Inc.

First Received on June 12, 2009.   Last Updated on December 6, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hunter Syndrome
Additional conditions recognized in this trial
Mucopolysaccharidosis II
More general conditions related to this trial
Carbohydrate Metabolism, Inborn Errors
Connective Tissue Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Heredodegenerative Disorders, Nervous System
Lysosomal Storage Diseases
Mental Retardation
Mental Retardation, X-Linked
Metabolic Diseases
Metabolism, Inborn Errors
Mucinoses
Mucopolysaccharidoses
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Interventions listed in this trial
Idursulfase-IT
Control
Sponsors listed in this trial
Shire Human Genetic Therapies, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services